About Prexton Therapeutics
Prexton Therapeutics is a company based in Plan-les-ouates (Switzerland) founded in 2012 was acquired by Lundbeck in March 2018. Prexton Therapeutics has raised $43.46 million across 3 funding rounds from investors including Lundbeck, Forbion and Seroba Lifesciences. Prexton Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Plan-les-ouates, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prexton Therapeutics
Prexton Therapeutics has successfully raised a total of $43.46M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Prexton Therapeutics
Prexton Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck, Forbion and Seroba Lifesciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Locked | Locked | Locked | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Locked | Locked | Locked | |
|
Investments are made by Sunstone in early-stage European companies.
|
Locked | Locked | Locked |
Investor details for Prexton Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Prexton Therapeutics
Investment portfolio details for Prexton Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Prexton Therapeutics
Detailed financials for Prexton Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Prexton Therapeutics Comparisons
Peer comparison for Prexton Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Prexton Therapeutics
Prexton Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| Locked | Locked | Locked |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| Locked | Locked | Locked |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
Detailed competitors of Prexton Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Prexton Therapeutics
Complete news archive for Prexton Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prexton Therapeutics
Prexton Therapeutics was founded in 2012.
Prexton Therapeutics is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Prexton Therapeutics is a funded company, having raised a total of $43.46M across 3 funding rounds to date.
Prexton Therapeutics was founded in 2012 and operates in the biotechnology sector, focusing on treatments for Parkinsons disease. Metabotropic glutamate receptors mGluR3 and mGluR4 are targeted through the development of positive allosteric modulators to enhance mGluR4 activity. These receptors interact with glutamate, an excitatory neurotransmitter linked to functions such as learning, memory, anxiety, and pain perception. Motor behaviors in Parkinsons patients are expected to be restored by this approach.
Prexton Therapeutics's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Prexton Therapeutics has 6 investors. Key investors include Lundbeck, Forbion, Seroba Lifesciences, Ysios Capital, and Sunstone.